Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST
about
From diagnosis to therapy in lung cancer: management of CT detected pulmonary nodules, a summary of the 2015 Chinese-German Lung Cancer Expert PanelImaging Biomarkers in ImmunotherapyThe Necrosis-Avid Small Molecule HQ4-DTPA as a Multimodal Imaging Agent for Monitoring Radiation Therapy-Induced Tumor Cell Death.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Response Evaluation of Chemotherapy for Lung Cancer.A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapyComplete pathological response to Imatinib mesylate in an extraintestinal gastrointestinal stromal tumorResponse assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome.Neutrophil:lymphocyte ratios and serum cytokine changes after hepatic artery chimeric antigen receptor-modified T-cell infusions for liver metastasesState of the art: Response assessment in lung cancer in the era of genomic medicineF-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapyUpdate on the role of imaging in management of metastatic colorectal cancerSurvival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.Viable tumor volume: Volume of interest within segmented metastatic lesions, a pilot study of proposed computed tomography response criteria for urothelial cancer.Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma.Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.New insight into the treatment of advanced differentiated thyroid cancer.Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or GefitinibRadiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitorsMolecular targeted therapies in non-GIST soft tissue sarcomas: what the radiologist needs to knowLongitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02)Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements.Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionEvaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases.Dynamic contrast-enhanced MRI coupled with a subtraction technique is useful for treatment response evaluation of malignant melanoma hepatic metastasisImmune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients.Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists.Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.Controversies in circulating tumor cell count during therapy.
P2860
Q28066842-8789C9E1-959D-4112-AAD8-00F1F345B04AQ28079871-B71ED410-455A-457D-9C62-471C3ADF8C88Q30370566-8AC0F29C-B5E6-46CC-A87E-03FAF9A673BDQ30651792-485282E4-DE0C-4F38-B369-E602309006F2Q33567345-C6553A02-D610-4D37-ABD9-DEC21723FC5FQ33779308-BBA768B9-C42B-4849-9114-8FF26DFF880EQ33830113-C090B7EC-7881-485F-9FFF-B21C536C7B7DQ33929944-44670760-E260-454F-8A23-1242D012369CQ34305765-DE389073-C5DB-480E-8419-0AB538EA1A25Q34537285-609D1150-D6C2-4686-9CAE-C5E14B5B54D9Q34577127-BCF5E039-74F1-4B90-984F-830D3CD20DBDQ34681069-82B0581A-B765-4ED3-A921-8425416C92F2Q35116993-38DE9778-45B3-41F0-872D-39C65E5BB4D0Q35285305-CE4CA263-2440-45C1-A5B3-B504C9468A60Q35504499-1B876921-1F71-48AC-9A75-6BDA73DDF0FDQ35668604-19FCF2DD-2476-427E-8145-C56C8AEB240CQ35984183-41D6B357-E99B-4A7C-9387-986FD3A1DA26Q36031518-F5FA24B9-59CC-431E-96F3-194B9633AEE5Q36132702-EDA220C2-40DF-4051-A644-AF721D2E5C16Q36528466-47F05C53-C90C-424E-8BD9-26B5B637CC8DQ36545344-AB6C988B-954D-4663-AC7A-5520EA5A7B36Q36553854-7EE2F83A-C403-4E3C-810B-016D7B8FD053Q36634305-A2F6E7A1-46EC-423D-BBA5-EC2395326B11Q36819466-669ACEFA-93CC-4A2D-AA06-1B1B87219D90Q36916399-0B0DBF52-9C89-4527-8444-06CC5E927190Q37021940-BA776837-7012-4D81-B91E-9DDFDB30E32CQ37024590-15519593-2A3B-4DA0-8E92-70DD6E4E7226Q37065818-A6F2C00E-224E-49A3-8611-BEE1B79089CFQ37088281-FE287644-93CB-4F05-A96E-C8E68B0FC72BQ37277324-55971605-DB10-4A6E-A0FD-775E67508853Q37280018-B5D1FAC9-DB31-420E-B3CD-FE7FD9455B11Q37350763-B1B554A7-E8B0-4EE3-9B45-565D878E733DQ37414589-A5D9ED07-E8A9-437C-8229-B75B87C2658DQ37437556-E491FB51-D972-4616-A1A5-38E12332B467Q37516943-89EA81CD-472A-4D1B-95A9-3578BEA28A3CQ37589535-CCD607EC-5731-4B57-BB97-1FEDB3458A5DQ37589551-74ABC6DA-9BC2-4322-8A15-F488811BC1AFQ37589557-28C24341-D966-42A7-9CF1-AE4D08D71756Q37673407-BE96D5C5-55C2-4982-B1A8-6A688289EA1BQ38115624-39A4E137-E131-48A7-8203-24CA7F1CDBFE
P2860
Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Personalized tumor response as ...... complement pitfalls of RECIST
@ast
Personalized tumor response as ...... complement pitfalls of RECIST
@en
type
label
Personalized tumor response as ...... complement pitfalls of RECIST
@ast
Personalized tumor response as ...... complement pitfalls of RECIST
@en
prefLabel
Personalized tumor response as ...... complement pitfalls of RECIST
@ast
Personalized tumor response as ...... complement pitfalls of RECIST
@en
P2093
P2860
P356
P1476
Personalized tumor response as ...... complement pitfalls of RECIST
@en
P2093
Geoffrey Shapiro
Hiroto Hatabu
Jyothi P Jagannathan
Katherine M Krajewski
Kevin O'Regan
Mizuki Nishino
Nikhil H Ramaiya
P2860
P304
P356
10.2214/AJR.11.7483
P407
P577
2012-04-01T00:00:00Z